The renin-angiotensin system and its vasoactive metabolite angiotensin-(1-7) in the mechanism of the healing of preexisting gastric ulcers. The involvement of mas receptors nitric oxide, prostaglandins and proinflammatory cytokines

Journal of Physiology and Pharmacology

Volumn 67, Issue 1, 2016, Pages 75-91

  Pawlik, M W ^a   Kwiecien, S ^a   Ptak Belowska, A ^a   Pajdo, R ^a   Olszanecki, R ^a   Suski, M ^a   Madej, J ^a   Targosz, A ^a   Konturek, S J ^a   Korbut, R ^a   Brzozowski, T ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Angiotensin II; Angiotensin (1 7); Gastric blood flow; Gastric oxygen uptake; Gastric ulcer healing; Interleukin 1 ; Mas receptor; Nitric oxide; Renin angiotensin system; Superoxide dismutase; Tumor necrosis factor

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN[1-7][7 DEXTRO ALANINE]; INDOMETACIN; INTERLEUKIN 1BETA; LISINOPRIL; LOSARTAN; MESSENGER RNA; N ETHYLCARBAMOYL 3 [4 (5 FORMYL 4 METHOXY 2 PHENYL 1 IMIDAZOLYLMETHYL)PHENYL] 5 ISOBUTYL 2 THIOPHENESULFONAMIDE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROSTAGLANDIN; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA; ANGIOTENSIN I (1-7); CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENZYME INHIBITOR; G PROTEIN COUPLED RECEPTOR; IMIDAZOLE DERIVATIVE; ONCOPROTEIN; PEPTIDE FRAGMENT; PROTO-ONCOGENE PROTEINS C-MAS-1; TUMOR NECROSIS FACTOR;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPPLER FLOWMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; GENE AMPLIFICATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NONHUMAN; OXYGEN CONSUMPTION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH ULCER; ULCER HEALING; ANIMAL; DRUG EFFECTS; METABOLISM; STOMACH MUCOSA; WISTAR RAT;

ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CYTOKINES; ENZYME INHIBITORS; GASTRIC MUCOSA; IMIDAZOLES; INDOMETHACIN; INTERLEUKIN-1BETA; LISINOPRIL; LOSARTAN; MALE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PEPTIDE FRAGMENTS; PROSTAGLANDINS; PROTO-ONCOGENE PROTEINS; RATS; RATS, WISTAR; RECEPTORS, G-PROTEIN-COUPLED; RENIN-ANGIOTENSIN SYSTEM; STOMACH ULCER; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84961664648     PISSN: 08675910     EISSN: 18991505     Source Type: Journal    
DOI: None     Document Type: Article

References (77)

1. Szabo S, Tache Y, Tarnawski A. The gastric cytoprotection concept of Andre Robert and the origins of a new series of international symposia. In: Cell/Tissue Injury and Cytoprotection/Organoprotection in the Gastrointestinal Tract: Mechanisms, Prevention and Treatment. L.P. Filaretova, K. Takeuchi (eds.) Frontiers in Gastrointest Research. Basel, Karger, 2012, 30, pp. 1-23.
2. 3 – transport: Characteristics and proposed role in acidity regulation and mucosal protection. Am J Physiol 1982; 242: G183-G193.
3. Oates PJ. Gastric blood flow and mucosal defense. In: Gastric Cytoprotection. D. Hollander, A.S. Tarnawski, (eds.). New York, Plenum Press, 1990, pp. 125-165.
4. Whittle BJ, Lopez-Belmonte J, Moncada S. Regulation of gastric mucosal integrity by endogenous nitric oxide: interaction with prostanoids and sensory neuropeptides in the rat. Br J Pharmacol 1990; 99: 607-611.
5. Laine L, Takeuchi K, Tarnawski A. Gastric mucosal defense and cytoprotection: bench to bedside. Gastroenterology 2008; 135: 41-60.
6. Tarnawski A, Ahluwalia A, Jones MK. Gastric cytoprotection beyond prostaglandins: cellular and molecular mechanisms of gastroprotective and ulcer healing actions of antacids. Curr Pharm Des 2013; 19: 126-132.
7. deFoneska A, Kaunitz JD. Gastroduodenal mucosal defense. Curr Opin Gastroenterol 2010; 26: 604-610.
8. Holm-Rutili L, Obring KJ. Rat gastric mucosal microcirculation in vivo. Am J Physiol 1985; 248: G741-G746.
9. Cheung LY, Ashley SW. Gastric blood flow and mucosal defense mechanisms. Clin Invest Med 1987; 10: 201-208.
10. Brzozowski T, Konturek PC, Konturek SJ, Brzozowska I, Pawlik T. Role of prostaglandins in gastroprotection and gastric adaptation. J Physiol Pharmacol 2005; 56 (Suppl. 5): 33-55.
11. Gyires K, Toth VE, Zadori ZS. Gastric mucosal protection: from the periphery to the central nervous system. J Physiol Pharmacol 2015; 66: 319-329.
12. Kiel JW, Shepherd AP. Gastrointestinal blood flow. In: Laser-Doppler Blood Flowmetry. P.A. Olberg, A.P. Shepherd (eds). Kluwer Academic Publishers 1990, pp. 227-250.
13. Kwiecien S, Jasnos K, Magierowski M, et al. Lipid peroxidation, reactive oxygen species and antioxidative factors in the pathogenesis of gastric mucosal lesions and mechanism of protection against oxidative stress-induced gastric injury. J Physiol Pharmacol 2014; 65: 613-622.
14. Jacobson ED. Circulatory mechanisms of gastric mucosal damage and protection. Gastroenterology 1992; 102: 1788-1800.
15. Tarnawski AS, Chai J, Jones MK. Esophageal and gastrointestinal microcirculation: Essential for mucosal protection, a targed for injury, and critical component of injury and and ulcer healing. In Organ Microcirculation. A Gateway to Diagnostic and Therapeutic Interventions. H. Ishii, M. Suemastsu, K. Tanishita, K. Suzuki (eds.). Keito University International Symposia for Life Sciences and Medicine. Springer, 2005, 13, pp. 49-61.
16. Kwiecien S, Konturek PC, Sliwowski Z, et al. Interaction between selective cyclooxygenase inhibitors and capsaicinsensitive afferent sensory nerves in pathogenesis of stressinduced gastric lesions. Role of oxidative stress. J Physiol Pharmacol 2012; 63: 143-151.
17. Ohno T, Hattori Y, Komine R, et al. Roles of calcitonin generelated peptide in maintenance of gastric mucosal integrity and in enhancement of ulcer healing and angiogenesis. Gastroenterology 2008; 134: 215-225.
18. Brzozowska I, Konturek PC, Brzozowski T, et al. Role of prostaglandins, nitric oxide, sensory nerves and gastrin in acceleration of ulcer ulcer healing by melatonin and its prekursor, L-tryptophan. J Pineal Res 2002; 32: 149-162.
19. Tache Y. Brainstem neuropeptides and vagal protection of the gastric mucosal against injury: role of prostaglandins, nitric oxide and calcitonin - gene related peptide in capsaicin afferents. Curr Med Chem 2012; 19: 35-42.
20. Fyhrquist F, Saijonmaa O. Renin-angiotensin system revisited. J Intern Med 2008; 264: 224-236.
21. Paul M, Poyan Mehr A, Kreutz R. Physiology of local rennin-angiotensin systems. Physiol Rev 2006; 86: 747-803.
22. Frandriks L. The renin-angiotensin system and the gastrointestinal mucosa. Acta Physiol (Oxf) 2011; 201: 157-167.
23. Hallersund P, Elfvin A, Helander HF, Fandriks L. The expression of renin-angiotensin system components in the human gastric mucosa. J Renin Angiotensin Aldosterone Syst 2011; 12: 54-64.
24. Heinemann A, Sattler V, Jocic M, Wienen W, Holzer P. Effect of angiotensin II and telmisartan, an angiotensin 1 receptor antagonist, on rat gastric mucosal blood flow. Aliment Pharmacol Ther 1999; 13: 347-355.
25. Brzozowski T, Ptak-Belowska A, Kwiecien S, et al. Novel concept in the mechanism of injury and protection of gastric mucosa: role of renin-angiotensin system and active metabolites of angiotensin. Curr Med Chem 2012; 19: 55-62.
26. Garg M, Angus PW, Burreli LM et al. Review article the pathophysiological roles of the renin-angiotensin system in the gastrointestinal tract. Aliment Pharmacol Ther 2012; 35: 414-428.
27. Ender F, Labancz T, Rosivall L. Protective effects of inhibition of the renin-angiotensin system against gastric mucosal lesions induced by cold-restraint in the rat. Acta Physiol Hung 1993; 81: 13-18.
28. Nakagiri A, Sunamoto M, Murakami M. Angiotensin AT1 receptor blockers suppress ischemia/reperfusion-induced gastric injury in rats. Inflammopharmacology 2007; 15: 171-174.
29. Mou D, Zhu X, Xu W, Du R. The pathogenetic role of endogenous angiotensin II in stress ulcer in obstructive jaundice rats. Chin Med J (Engl) 1998; 111: 309-312.
30. Bregonzio C, Armando I, Ando H, Jezova M, Baiardi G, Saaverdra JM. Angiotensin II AT1 receptor blockade prevents gastric ulcers during cold-restrain stress. Ann NY Acad Sci 2004; 1018: 351-355.
31. Pawlik MW, Sendur R, Biernat J. et al. Inhibition of the renin-angiotensin system protects gastric mucosa against ischemia/reperfusion injury. Gastroenterology 2001; 120 (Suppl 1): 1031.
32. Bregonzio C, Armando I, Ando H, Jezova M, Baiardi G, Saavedra JM. Anti-inflammatory effects of angiotensin II AT1 receptor antagonism prevent stress-induced gastric injury. Am J Physiol Gastrointest Liver Physiol 2001; 285: G414-G423.
33. Pawlik W, Shepherd AP, Jacobson ED. Effects of vasoactive agents on intestinal oxygen consumption and blood flow in dogs. J Clin Invest 1975; 56: 484-490.
34. Pawlik W, Biernat J, Sendur R, Obuchowicz R, Brzozowski T, Konturek SJ. Involvement of reninangiotensin system in the control of gastrointestinal blood flow, oxygen uptake and protection. J Physiol Pharmacol 2009; 60 (Suppl. 2): 72.
35. Miyazaki M, Takai S, Jin D, Muramatsu M. Pathological roles of angiotensin II produced by mast cell chymase and the effects of chymase inhibition in animal models. Pharmacol Ther 2006; 112: 668-676.
36. Ferrario CM, Iyer SN. Angiotensin-(1-7): a bioactive fragment of the rennin-angiotensin system. Regul Pept 1998; 78: 13-18.
37. Santos RA, Ferreira AJ, Simoes e Silva AC. Recent advances in the angiotensin-converting enzyme2-angiotensin (1-7)- Mas axis. Exp Physiol 2008; 93: 519-527.
38. Clark MA, Diz DI, Tallant EA. Angiotensin-(1-7) down regulates the angiotensin II type receptor in vascular smooth muscle cells. Hypertension 2001; 37: 1141-1146.
39. Brosnihan KB. Effect of the angiotensin-(1-7) peptide on nitric oxide release. Am J Cardiol 1998; 82 (10A): 17S-19S.
40. Sampaio WO, Souza des Santos RA, Faria-Silva R, da Mata Machado LT, Schriffrin EL, Touyz RM. Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension 2007; 49: 185-192.
41. Jaiswal N, Diz DI, Chappell MC, Khosla MC, Ferrario CM. Stimulation of endothelial cell prostaglandin production by angiotensin peptides. Hypertension 1992; 19 (Suppl. 2); 49-55.
42. Olszanecki R, Madej J, Suski M, Gebska A, Bujak-Gizycka B, Korbut R. Angiotensin metabolism in rat stomach wall: prevalence of angiotensin-(1-7) formation. J Physiol Pharmacol 2009: 60: 191-196.
43. Zhu D, Tong Q, Liu W, et al. Angiotensin (1-7) protects against stress-induced gastric lesions in rats. Biochem Pharmacol 2014; 87: 467-476.
44. Okabe S, Roth JL, Pfeiffer CJ. A method for experimental penetrating gastric and duodenal ulcers in rats. Observations on normal healing. Am J Dig Dis 1971; 16: 277-284.
45. Konturek SJ, Brzozowski T, Majka J, Pytko-Polonczyk J, Stachura J. Inhibition of nitric oxide synthase delays healing of chronic gastric ulcers. Eur J Pharmacol 1993; 239: 215 -217.
46. Konturek SJ, Konturek PC, Brzozowski T. Prostaglandins and ulcer healing. J Physiol Pharmacol 2005; 56 (Suppl. 5): 5-31.
47. Kiel JW, Shepherd AP. A microcomputer oximeter for whole blood. Am J Physiol 1983; 244: H722-H725.
48. Kiel JW, Shepherd AP. Continuous measurement of arteriovenous oxygen difference and VO2 by microcomputer. Am J Physiol 1983; 245: H178-H182.
49. Pawlik MW, Obuchowicz R, Biernat J, et al. Effects of peripherally and centrally applied ghrelin in the pathogenesis of ischemia-reperfusion induced injury of the small intestine. J Physiol Pharmacol 2011; 62: 429-439.
50. Green LC, Tannenbaum SR, Goldman P. Nitrate synthesis in the germ-free and conventional rat. Science 1981; 212: 56-58.
51. Sun J, Zhang X, Broderick M, Fein H. Measurement of nitric oxide production in biological systems by using Griess reaction assay. Sensors 2003; 3: 276-284.
52. Brzozowski T, Konturek PC, Konturek SJ. Nitric oxidereleasing agents a new generation of drugs for gastrointestinal diseases. Front Gastrointest Res 2002; 25: 158-165.
53. Pawlik M, Pajdo R, Kwiecien S, et al. Nitric oxide (NO)- releasing aspirin exhibits a potent esophagoprotection in experimental model of acute reflux esophagitis. Role of nitric oxide and proinflammatory cytokines. J Physiol Pharmacol 2011; 62: 75-86.
54. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinum thiocyanate-phenolchloroform extraction. Anal Biochem 1987; 162: 156-159.
55. Olszanecki R, Bujak-Gizycka B, Madej J, et al. Kaempferol but not resveratrol inhibits angiotensin converting enzyme. J Physiol Pharmacol 2008; 59: 387-392.
56. Olszanecki R, Suski M, Gebska A, et al. The influence of angiotensin-(1-7) peptidomimetic (AVE 0991) and nebivolol on angiotensin I metabolism in aorta of apoE-knockout mice. J Physiol Pharmacol 2013; 64: 317-320.
57. Brzozowski T, Kwiecien S, Szlachcic A, et al. Involvement of renin-angiotensin system and vasoactive angiotensin-(1- 7) metabolite of angiotensin II in gastric mucosal injury and gastroprotection. In: Filaretova LP, Takeuchi K. eds. Cell/Tissue Injury and Cytoprotection/Organoprotection in the Gastrointestinal Tract: Mechanisms, Prevention. L.P. Filaretova, K. Takeuchi, (eds.). Front Gastrointest Research Basel, Karger, 2012, 30, pp. 181-190.
58. Santos RA, Campagnole-Santos MJ, Andrade SP. Angiotensin-(1-7): an update. Regul Pept 2000; 91: 45-62.
59. Sampaio WO, Nascimento AA, Santos RA. Systemic and regional hemodynamics effects of angiotensin-(1-7) in rats. Am J Physiol Heart Circ Physiol 2003; 284: H1985-H1994.
60. Abbas A, Gorelik G, Garbini LA, Scicli AG. Angiotensin-(1- 7) induces bradykinin mediated hypotensive responses in anesthetized rats. Hypertension 1997; 30: 217-221.
61. Santos RA, Ferreira AJ. Pharmacological effects of AVE 0991, a nonpeptide angiotensin-(1-7) receptor agonist. Cardiovasc Drug Rev 2006; 24: 239-246.
62. Nguyen Dinh Cat A, Touyz RM. A new look at the reninangiotensin system - focusing on the vascular system. Peptides 2001; 32: 2141-2150.
63. Santos RA, Ferreira AJ, Verano-Braga T, Bader M. Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin angiotensin system. J Endocrinol 2013; 216: R1-R17.
64. Santos RA. Angiotensin-(1-7). Hypertension 2014; 63: 1138-1147.
65. Simoes e Silva AC, Silveira KD, Ferreira AJ, Teixeira MM. ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis. Br J Pharmacol 2013;169: 477-492.
66. Kwiecien SJ, Jasnos K Magierowski M, et al. Lipid peroxidation, reactive oxygen species and antioxidative factors in the pathogenesis of gastric mucosal lesions and mechanism of protection against oxidative stress-induced gastric injury. J Physiol Pharmacol 2014; 65: 613-622.
67. Bhatttacharyya A, Chattopadhyay R, Mitra S, Crowe SE. Oxidative stress: an essential factor in the pathogenesis of gastrointestinal diseases. Physiol Rev 2014; 94: 329-354.
68. Wang T, Zhou YT, Chen XN, Zhu AX, Wu BH. Remote ischemic postconditioniong protects against gastric mucosal lesions in rats. World J Gastroenterol 2014; 20: 9519-9527.
69. Pawlik MW, Sendur R, Biernat J, Brzozowski T, Konturek SJ, Pawlik WW. Involvement of nitric oxide and prostaglandins in the angiotensin 1-7 induced acceleration of the healing of experimental gastric ulcers. Gastroenterology 2010; 138 (Suppl. 1): S-131.
70. Brzozowski T, Kwiecien S, Szlachcic A, et al. Involvement of renin-angiotensin system and angiotensyn-(1-7) metabolite of angiotensin II in gastric mucosal injury and gastroprotection. In: Cell/Tissue Injury and Cytoprotection/Organoprotection in the Gastrointestinal Tract: Mechanisms, Prevention and Treatment. L.P. Filaretowa, K. Takeuchi (eds.). Frontiers in Gastrointestinal Research. Basel, Karger, 2012, 30, pp. 181-190.
71. Schmassmann A, Peskar BM, Stettler C, et al. Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro-intestinal ulcer models in rats. Br J Pharmacol 1998; 123: 795-804.
72. Brzozowski T, Konturek PC, Pajdo R, et al. Physiological mediators in nonsteroidal anti-inflammatory drugs (NSAIDs)-induced impairment of gastric mucosal defense and adaptation. Focus on nitric oxide and lipoxins. J Physiol Pharmacol 2008; 59 (Suppl. 2): 89-102.
73. Jackson ML, Wu KC, Mahida YR, Jenkins D, Hawkey CJ. Cyclooxygenase (COX) 1 and 2 in normal, inflamed, and ulcerated human gastric mucosa. Gut 2000; 47: 762-770.
74. Ruiz-Ortega M, Lorenzo O, Suzuki Y, Ruperez M, Egido J. Proinflammatory actions of angiotensins. Cur Opin Nephrol Hypertens 2001;10: 321-329.
75. Silveira KD, Coelho FM, Vieira AT, at al. Anti-inflammatory effects of the activation of the angiotensin-(1-7) receptor, Mas, in experimental models of arthritis. J Immunol 2010; 185: 5569-5576.
76. Mansoori A, Oryan S, Nematbakhsh M. Role of Mas receptor antagonist (A779) on pressure diuresis and natriuresis and renal blood flow in the absence of angiotensin II receptors type 1 and 2 in female and male rats. J Physiol Pharmacol 2014; 65: 633-639.
77. Liu, Y, Li B, Wang X, et al. Angiotensin-(1-7) suppresses hepatocellular carcinoma growth and angiogenesis via complex interactions of angiotensin II type 1 receptor, angiotensin II type 2 receptor and Mas receptor. Mol Med 2015; 21:626-636.